Academic Training in Therapeutic Advancement for Child Health (ATTACH)

虽然近年来成人药物治疗取得了巨大的进步，但扩大了 这些新疗法对婴儿和儿童的益处仍然是一个重大挑战。重要发展 药代动力学、药效学、疾病表现和进展的变化都阻碍了直接 将成人治疗学翻译成儿科。儿科临床药理学学科提供了 必要的发展生理学培训，以利用现有知识并指导合理的治疗 对婴儿和儿童来说。然而，目前的药理学家和儿科专科专家与正规的 临床药理学方面的培训既少又老化。其他儿科临床医生-接受过以下培训的科学家 迫切需要临床药理学，以确保为婴儿和儿童优化治疗。在……里面 2015年，在PharmD(儿科药代动力学(PK)建模专家)Edmund Capparelli的领导下 和Adriana Treouse let，医学博士，MAS(儿科临床试验专家)，儿科临床药理学培训 加州大学圣地亚哥分校被正式确定为NICHD支持的T32培训计划。我们为这第一次迭代感到自豪 提供儿科临床药理学前沿研究培训的正式计划。我们现在提议 更新我们的T32儿科临床药理学培训计划，题为“治疗学的学术培训” 促进儿童健康“(附后)。在这次更新中，我们自豪地寻求(1)通过以下方式使我们的计划现代化 新的项目领导，(2)招聘更多世界知名的教师来教授我们的研究员最新的技术 技术，(3)推出一个系统的工具来评估我们计划的表现并协助计划 改进，(4)强调实习生和教师导师培训，以及(5)加强招聘方法，以吸引 更加多样化的申请者和受训人员池，以促进劳动力的多样性。我们的主要目标是 我们的第一个培训周期将保持不变：(1)增加儿科临床人数 从事应用于儿童健康的临床药理学研究的药理学家和临床医生科学家； (2)吸引优秀的年轻儿科临床医生到加州大学圣迭戈分校，并通过以下方式扩大他们的翻译能力 临床药理学方法；(3)在以下指导下促进见习医生的职业发展 世界级的，公认的调查员-教师导师；和(4)培养妇女和少数民族的早期职业生涯 儿科治疗学的研究人员。与我们令人印象深刻的导师团队一起，他们拥有出色的培训轨迹 记录，加州大学圣迭戈分校的附属研究员将成为明天儿科临床药理学的领导者。

While tremendous advances in pharmacotherapy for adults have been achieved in recent years, expanding the benefits of these new therapies to infants and children remains a significant challenge. Important developmental changes in pharmacokinetics, pharmacodynamics, disease presentation and progression all impede direct translation of adult therapeutics into pediatrics. The discipline of pediatric clinical pharmacology provides necessary training in developmental physiology to leverage existing knowledge and guide rational therapeutics for infants and children. However, the current pool of pharmacologists and pediatric sub-specialists with formal training in clinical pharmacology is both small and aging. Additional pediatric clinician-scientists with training in clinical pharmacology are urgently needed to ensure that therapies are optimized for infants and children. In 2015, under the leadership of Edmund Capparelli, PharmD (expert in pediatric pharmacokinetic (PK) modeling) and Adriana Tremoulet, MD, MAS (expert in pediatric clinical trials), training in pediatric clinical pharmacology at UC San Diego was formalized as a NICHD-supported T32 Training Program. We are proud of this first iteration of a formal program to provide cutting-edge research training in pediatric clinical pharmacology. We now propose a renewal of our T32 pediatric clinical pharmacology training program, entitled “Academic Training in Therapeutic Advancement for Child Health” (ATTACH). In this renewal, we proudly seek to (1) modernize our program with new program leadership, (2) recruit more world-renowned faculty to teach our fellows state-of-the-art technologies, (3) launch a systematic tool to assess performance of our program and assist in program improvement, (4) emphasize trainee and faculty mentor training, and (5) enhance recruitment methods to attract a more diverse pool of applicants and trainees to stimulate diversity in the workforce. Our key objectives of the first cycle of our training program will remain the same: (1) To increase the number Pediatric clinical pharmacologists and Clinician-Scientists engaged in clinical pharmacology research as applied to child health; (2) to attract outstanding young pediatric clinicians to UCSD and to expand their translational capacity through clinical pharmacology methods; (3) to facilitate career development of ATTACH trainees under the guidance of world class, established investigator-faculty mentors; and (4) to cultivate the early careers of women and minority investigators in pediatric therapeutics. With our impressive group of mentors with outstanding training track records, UCSD ATTACH Fellows will be poised to be tomorrow's leaders in pediatric clinical pharmacology.